Pomerantz LLP is investigating Omeros Corporation for possible securities fraud following the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issuing a negative opinion on Omeros's marketing authorization application for narsoplimab, a treatment for TA-TMA. The announcement caused Omeros's stock to fall 19.12% on June 26, 2026. The investigation focuses on whether Omeros and its officers engaged in unlawful business practices related to this event. Investors affected are encouraged to contact Pomerantz LLP for potential class action participation.
BitFuFu Inc. reported a Q2 2026 earnings per share of -$0.02, missing estimates and showing a 100% earnings surprise. Revenue fell 62.9% year-over-year to $42.8 million, driven by a 27.5% drop in Bitcoin price and lower demand for cloud mining, resul...
Sensus Healthcare reported a sharp decline in Q2 revenue to $2.3 million, down from $7.3 million last year, due to delayed financing for its SRT-100 medical devices. The company has severed ties with the problematic bank causing the delays and expect...
Duos Technologies Group (DUOT) has sold its rail technology subsidiary to focus on the AI data center market, securing over $500 million in five-year hosting service contracts with Axe Compute Inc. The company reported Q2 earnings per share of $0.66 ...
Shopify reported strong Q2 2026 earnings, surpassing analyst expectations thanks to significant growth in AI-driven commerce. AI-driven traffic and orders to Shopify stores tripled year-over-year, boosting confidence in the company's AI innovation. S...
Freightos Limited reported Q2 results surpassing expectations with an EPS of -$0.03 versus -$0.05 expected and record revenue of $7.7 million, driven by a 19% increase in core platform revenue. The company narrowed its adjusted EBITDA loss to $2 mill...
